Health & Biotech
ScoPo’s Powerplays: The immune oncology space finally gets long overdue attention
Health & Biotech
These ASX biotechs are on the verge of releasing Phase III clinical trial results
Health & Biotech
Apiam expands dominant footprint in regional markets with major Queensland acquisition
Health & Biotech
Breast cancer play Volpara delivers full-year bumper revenue, share price up 5pc
Health & Biotech
Creso Pharma’s takeover target poised to enter lucrative US market
Health & Biotech
Invion led a group of ASX cancer stocks up after promising news
Health & Biotech
Health Kick: Injectable contrast dyes have serious health impacts, Osprey Medical has the solution
Health & Biotech
MGC Pharma ready to march ahead with three clinical trials in 2021
Health & Biotech
Health Kick: CEO Rob Wong on how Control Bionics is enabling communication via brain signals
Health & Biotech
Neurotech hits another key milestone with unique drug therapy in the US$25bn market for multiple sclerosis treatments
Health & Biotech
Introducing Opin, Opyl’s AI platform that recruits clinical trial patients from around the world
Health & Biotech
‘Tidal wave of demand’: There’s a pot shortage in New York
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.